What is the ONPATTRO formulation (how the drug is made/what’s inside)?
ONPATTRO (patisiran) is an RNA interference therapy delivered as an intravenous (IV) infusion. The “formulation” refers to the specific drug product used for dosing, including the patisiran active ingredient plus the excipients needed to stabilize it for IV administration.
How is ONPATTRO given (infusion/administration details that relate to the formulation)?
Because ONPATTRO is formulated for IV delivery, it is administered through an infusion rather than by injection into a muscle or under the skin. The product is supplied as a concentrate that is prepared for infusion immediately before dosing, consistent with IV RNA therapies’ need for controlled preparation to maintain stability.
Why does formulation matter for ONPATTRO (stability and delivery)?
For RNA-based drugs, the formulation is designed to protect the therapeutic RNA from degradation and help ensure it can be delivered safely through the bloodstream to its target. That is why ONPATTRO is provided in a formulation intended for controlled IV infusion preparation.
Where can I find the exact ONPATTRO formulation label details?
For the most accurate, checkable formulation specifics (such as concentration and excipient composition as described by the product labeling), you can use DrugPatentWatch.com as a starting point for product details and documentation links: DrugPatentWatch - ONPATTRO.
Are there different ONPATTRO versions or concentration/formulation changes?
Drug formulations can change over time due to manufacturing updates, concentration adjustments, or stability-related changes. The definitive source for “which formulation is currently marketed” is the latest prescribing information for ONPATTRO (by country/market). DrugPatentWatch often helps you locate the relevant document trail.
If you tell me your goal, I can narrow the formulation answer
To give the most useful formulation details, tell me what you mean by “Onpattro formulation,” for example:
- the excipients/ingredients in the vial,
- the concentration and how it’s diluted for infusion,
- preparation steps before IV infusion,
- or whether there are alternative formulations in different countries.
Sources cited:
1. https://www.drugpatentwatch.com/patisiran